Disease Comparison(疾病比较)研究综述
Disease Comparison 疾病比较 - Finally, we performed cross-disease comparisons and druggable pocket predictions, identifying inflammatory targets that are specific to and tractable for nephrolithiasis. [1] Our meta-analysis and cross-disease comparisons identified consistent microbial alterations in each enteropathy, revealed microbial ecosystems among marker bacteria in distinct states, and demonstrated the necessity and feasibility of metagenome-based multidisease classifications. [2] Indeed, this signature of matrix proteins was consistently modulated across all age and disease comparisons and the increase in interstitial matrix was also observed in human kidney disease datasets. [3] The utility of [18F]FDG-PET in dementia with Lewy bodies (DLB) needs further validation by considering large samples of patients and disease comparisons and applying state-of-the-art statistical methods. [4] While generic HRQoL instruments are typically more extensively validated and allow for cross-disease comparisons, dermatology-specific instruments may have better responsiveness to change, which is important when evaluating the impact of treatment in clinical trials or routine practice. [5] Intestinal diseases can share clinical symptoms and gut microbiome alterations, necessitating cross-disease comparisons and the use of multi-disease models. [6]最后，我们进行了跨疾病比较和药物袋预测，确定了肾结石特异性和可治疗的炎症靶点。 [1] 我们的荟萃分析和跨疾病比较确定了每种肠病中一致的微生物改变，揭示了处于不同状态的标记细菌之间的微生物生态系统，并证明了基于宏基因组的多疾病分类的必要性和可行性。 [2] 事实上，在所有年龄和疾病比较中，基质蛋白的这种特征一直受到调节，并且在人类肾脏疾病数据集中也观察到间质基质的增加。 [3] [18F]FDG-PET 在路易体痴呆 (DLB) 中的效用需要通过考虑大量患者样本和疾病比较以及应用最先进的统计方法来进一步验证。 [4] 虽然通用 HRQoL 工具通常经过更广泛的验证并允许进行跨疾病比较，但皮肤科专用工具可能对变化具有更好的响应能力，这在评估临床试验或常规实践中的治疗影响时很重要。 [5] 肠道疾病可以共享临床症状和肠道微生物组改变，因此需要进行跨疾病比较和使用多疾病模型。 [6]
disease comparison cohort
Women in the disease comparison cohort had not used adalimumab in pregnancy (N = 120). [1] The cohort study included 257 women with Crohn’s disease or rheumatoid arthritis in the adalimumab cohort who received at least one dose in the first trimester, 120 women in the disease comparison cohort who had not received adalimumab, and 225 women in the healthy comparison cohort. [2]疾病比较队列中的女性在妊娠期未使用阿达木单抗（N = 120）。 [1] 该队列研究包括阿达木单抗队列中的 257 名患有克罗恩病或类风湿性关节炎的女性，她们在孕早期至少接受了一次剂量，疾病比较队列中的 120 名女性未接受阿达木单抗治疗，健康对照组中的 225 名女性。 [2]